<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05103956</url>
  </required_header>
  <id_info>
    <org_study_id>TIROPATCH</org_study_id>
    <nct_id>NCT05103956</nct_id>
  </id_info>
  <brief_title>Hemostatic Patch/Collagen Sealant and Polyethylene Glycol (Hemopatch) in the Postoperative of the Thyroidectomy.</brief_title>
  <official_title>Regular Treatment Versus Hemostatic Patch/Collagen Sealant and Polyethylene Glycol (Hemopatch) in the Immediate Postoperative of the Thyroidectomy, Unicentric Study, Non-inferiority, Open and Randomized (Tiropatch Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational study with non-inferiority, prospective, randomized (1: 1) and open-label&#xD;
      medical device. The study has 2 treatment groups (HEMOPATCH® versus standard hemostasis).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective is to determine if there is a reduction in the volume of exudate in the&#xD;
      surgical bed with the application of the collagen and polyethylene glycol hemostatic agent.&#xD;
&#xD;
      The present study includes patients undergoing total thyroidectomy for multinodular goiter in&#xD;
      the Endocrine Surgery Unit of the Virgen del Rocío University Hospital.&#xD;
&#xD;
      The estimated sample calculation of patients enrolled in the study is 108 (2 groups, 1:1&#xD;
      ratio).&#xD;
&#xD;
      The patients don´t know what type of hemostatic the patients are going to receive (single&#xD;
      blind).&#xD;
&#xD;
      The duration of patient follow-up will be 30 +/- 10 days after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of changes in the exudate volume of the surgical bed with the application of the hemostatic agent of collagen and polyethylene glycol.</measure>
    <time_frame>Up to 18 hours.</time_frame>
    <description>Fixed periods of time will be established to evaluate the exudate from the surgical bed.&#xD;
It will be evaluated 18 hours after surgery by cervical ultrasound.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of changes in the patient's symptoms in the postoperative period of thyroidectomy after the application of the hemostatic agent of collagen and polyethylene glycol.</measure>
    <time_frame>Up to 4 weeks.</time_frame>
    <description>Decrease in the number of dyspnea at 24 hours and 30 days postoperatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in patient satisfaction after the application of the collagen and polyethylene glycol hemostatic agent, in relation to the surgical experience in the postoperative period of thyroidectomy.</measure>
    <time_frame>Up to 4 weeks.</time_frame>
    <description>Satisfaction survey at discharge and 30 days after the intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of improvement in postoperative complications of thyroidectomy after the application of the collagen and polyethylene glycol hemostatic agent.</measure>
    <time_frame>Up to 4 weeks.</time_frame>
    <description>Performance of the Trousseau test every 8 hours from surgery to hospital discharge and Calcemia (mg/dl) at discharge and at check-up in consultations (30 days) with total proteins.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of adverse effects after the use of the collagen and polyethylene glycol hemostatic agent in thyroid surgery.</measure>
    <time_frame>Up to 24 weeks.</time_frame>
    <description>Number of adverse events that have occurred in study patients.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Goiter</condition>
  <arm_group>
    <arm_group_label>Group A (Study Group)</arm_group_label>
    <description>HEMOPATCH® (Sealing / hemostatic patch of collagen and e polyethylene glycol)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (Control Group)</arm_group_label>
    <description>No hemostatic or the standard (ligatures and oxidized cellulose regenerated).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The present study includes older patients who underwent total thyroidectomy for&#xD;
        multinodular goiter in the Endocrine Surgery Unit of the Virgen del Rocío University&#xD;
        Hospital. They must sign an informed consent and know the study procedures that are&#xD;
        detailed in the protocol.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of legal age.&#xD;
&#xD;
          -  Indication of total thyroidectomy due to multinodular goiter.&#xD;
&#xD;
          -  Accept to enter the study and sign the informed consent.&#xD;
&#xD;
          -  Patient willing and able to complete clinical trial procedures, as described described&#xD;
             in the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under 18 years of age.&#xD;
&#xD;
          -  Patients with surgical indication for hemithyroidectomy or subtotal thyroidectomy (eg&#xD;
             unilateral nodular goiters).&#xD;
&#xD;
          -  Multinodular goiter with high suspicion or preoperative diagnosis of cancer (Bethesda&#xD;
             V and VI and / or infiltration of neighboring structures on imaging tests).&#xD;
&#xD;
          -  Known allergy or hypersensitivity to a component of the Hemopatch® investigational&#xD;
             treatments, riboflavin, or bovine proteins.&#xD;
&#xD;
          -  Concurrent or prior therapy with systemic pharmacological agents that promote blood&#xD;
             clotting, including, but not limited to, tranexamic acid, activated factor VII,&#xD;
             fibrinogen, and aprotinin.&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Refuse to enter the study and sign the informed consent.&#xD;
&#xD;
          -  Not agreeing to carry out all the planned follow-up.&#xD;
&#xD;
          -  Concurrent participation in another clinical trial with a medical device or drug or&#xD;
             with interfering endpoints Inability to understand the nature and scope of the trial&#xD;
             and the required procedures.&#xD;
&#xD;
        Criteria to be verified during surgery (Intraoperative exclusion criteria):&#xD;
&#xD;
          -  Persistent major bleeding after primary hemostasis.&#xD;
&#xD;
          -  Infection of the surgical area.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Manuel Martos Martínez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospitales Universitarios Virgen del Rocío</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juan Manuel Martos Martínez</last_name>
    <phone>955 01 20 00</phone>
    <email>jmmartos66@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carlos García Pérez</last_name>
    <phone>955 04 31 27</phone>
    <email>administracion.eecc.hvm.sspa@juntadeandalucia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Manuel Martos Martinez</last_name>
      <phone>955 01 20 00</phone>
      <email>jmmartos66@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Carlos García Pérez</last_name>
      <phone>955 04 31 27</phone>
      <email>administracion.eecc.hvm.sspa@juntadeandalucia.es</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goiter</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

